Last updated: September 5, 2026
Asparaginase erwinia chrysanthemi (recombinant)-rywn, marketed by Jazz Pharmaceuticals as Rylaze, is a recombinant Erwinia asparaginase used in multi-agent chemotherapy for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The product addresses patients who develop hypersensitivity to E. coli-derived asparaginase products.
Rylaze has become a material Jazz product because it replaces the discontinued or supply-constrained Erwinaze franchise and captures demand in a specialized oncology market. Jazz reported Rylaze net sales of approximately $253 million in 2022, $376 million in 2023, and about $500 million in 2024, indicating rapid post-launch expansion. The product has no conventional Orange Book or Paragraph IV pathway because it is regulated as a biologic under a biologics license application (BLA), not as a small-molecule drug under an NDA. [1-3]
What is asparaginase erwinia chrysanthemi (recombinant)-rywn?
Rylaze is recombinant crisantaspase, an L-asparaginase enzyme produced using a genetically modified microorganism. It depletes circulating asparagine, an amino acid required by leukemic lymphoblasts that have limited capacity to synthesize asparagine independently.
The FDA approved Rylaze on June 30, 2021, under BLA 761179. Its indication covers adult and pediatric patients with ALL or LBL as a component of a multi-agent chemotherapeutic regimen who have developed hypersensitivity to E. coli-derived asparaginase. [4]
Key product characteristics
| Attribute |
Rylaze |
| Active ingredient |
Asparaginase Erwinia chrysanthemi (recombinant)-rywn |
| Brand |
Rylaze |
| Sponsor |
Jazz Pharmaceuticals |
| FDA application |
BLA 761179 |
| FDA approval |
June 30, 2021 |
| Therapeutic area |
Acute lymphoblastic leukemia and lymphoblastic lymphoma |
| Administration |
Intramuscular injection |
| Common labeled strength |
10 mg/0.5 mL single-dose vial |
| Manufacturing platform |
Recombinant production of Erwinia chrysanthemi asparaginase |
| Primary use |
Replacement asparaginase for patients hypersensitive to E. coli-derived products |
Rylaze is generally administered at frequent intervals because native Erwinia asparaginase has a shorter duration of activity than pegylated E. coli-derived products. Its dosing schedule creates more injections but provides an alternative when continued asparaginase exposure is clinically important.
What is the FDA regulatory status and exclusivity timeline for Rylaze?
Rylaze received FDA approval in 2021 and benefits from biologic regulatory exclusivity rather than Hatch-Waxman small-molecule exclusivity.
| Milestone |
Date or status |
| FDA approval |
June 30, 2021 |
| Reference product category |
Biologic |
| Estimated 12-year BPCIA exclusivity |
Through approximately June 30, 2033 |
| Potential pediatric extension |
Could extend exclusivity by six months if applicable |
| Orange Book listing |
Not applicable |
| Paragraph IV certification |
Not applicable |
| Biosimilar pathway |
351(k) pathway |
| Orphan exclusivity |
Not the primary commercial protection cited for Rylaze |
The 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act generally prevents FDA approval of a biosimilar referencing the product before the statutory period expires. The date does not necessarily prevent a biosimilar sponsor from filing or conducting development activities earlier, and patent disputes can affect the actual launch date. [5]
When does Rylaze lose regulatory exclusivity?
Absent a pediatric extension or other adjustment, the core biologic exclusivity period is expected to end in 2033. A six-month pediatric extension, if available and properly earned, could move the regulatory exclusivity endpoint to approximately December 2033.
This date is distinct from patent expiry. Patent claims covering manufacturing, formulation, dosing, or specific product characteristics may expire later than regulatory exclusivity, while some claims may expire earlier.
What patents protect Rylaze?
Rylaze is protected through a combination of biologic regulatory exclusivity and patent rights covering the recombinant enzyme, formulations, dosing methods, manufacturing processes, and product quality attributes.
Unlike small-molecule products, Rylaze does not have an Orange Book patent listing. FDA does not use the Orange Book to publish BLA patent information. Patent disputes involving a future biosimilar would generally proceed under the BPCIA patent-exchange framework rather than through a Paragraph IV certification.
Which patent categories matter most?
The commercially relevant patent categories are likely to include:
- Recombinant asparaginase compositions and sequence variants.
- Host-cell and fermentation methods.
- Purification and stabilization processes.
- Injectable formulations and storage conditions.
- Dosing methods for patients hypersensitive to E. coli-derived asparaginase.
- Methods for maintaining therapeutic asparaginase activity during multi-agent chemotherapy.
Process patents can be commercially important even when a biosimilar developer designs around composition claims. Recombinant enzyme manufacturing requires control of activity, aggregation, impurities, immunogenicity, and batch consistency. A biosimilar entrant must show analytical similarity and clinical comparability, while also establishing a reliable commercial manufacturing process.
How strong is the Rylaze patent estate?
The Rylaze estate appears commercially meaningful but is not easily reduced to one blocking patent. Its principal strength is the combination of:
- biologic exclusivity through roughly 2033;
- a specialized recombinant manufacturing process;
- a narrow but clinically important hypersensitivity indication;
- limited treatment alternatives for patients unable to tolerate E. coli-derived products;
- manufacturing and quality-control barriers associated with enzyme biologics.
The estate is less insulated if competitors develop a different Erwinia-derived product, a novel recombinant asparaginase, or an alternative enzyme platform that does not rely on Jazz’s manufacturing claims.
What is the Orange Book status of Rylaze?
Rylaze has no conventional Orange Book status because it is approved under a BLA rather than an NDA.
| Regulatory issue |
Rylaze status |
| Orange Book listing |
No |
| NDA patent listing |
No |
| Paragraph IV challenge |
Not applicable |
| Purple Book reference-product status |
Yes, as a licensed biologic |
| Potential abbreviated competitor route |
351(k) biosimilar application |
| Small-molecule generic substitution |
Not applicable |
A future biosimilar sponsor would need to pursue the FDA’s 351(k) pathway. The product would not be substituted through ordinary state generic-substitution rules in the same manner as a conventional small-molecule generic.
What is Rylaze’s financial trajectory?
Rylaze has shown a rapid commercial ramp since launch. Jazz’s public filings indicate the following approximate net product sales:
| Fiscal year |
Rylaze net sales |
Commercial development |
| 2021 |
Launch year |
Initial U.S. rollout |
| 2022 |
Approximately $253 million |
First full commercial year |
| 2023 |
Approximately $376 million |
Continued conversion from Erwinaze and market penetration |
| 2024 |
Approximately $500 million |
Expansion of the replacement-asparaginase franchise |
The increase from approximately $253 million in 2022 to $376 million in 2023 represents growth of nearly 49%. Growth into 2024 was lower in percentage terms but still substantial, with sales approaching the half-billion-dollar range. [1-3]
What is driving Rylaze revenue growth?
The main revenue drivers are:
- replacement of Erwinaze demand after supply and commercial limitations;
- increased recognition of the need to maintain asparaginase exposure after hypersensitivity;
- adoption by pediatric oncology centers;
- Jazz’s established relationships in hematology-oncology;
- high treatment value relative to the small eligible patient population;
- recurring use across multi-month chemotherapy protocols.
Rylaze is a specialty product with a concentrated customer base. Its value is determined less by broad prescription volume than by treatment completion, dosing frequency, reimbursement, and continued availability during intensive pediatric oncology protocols.
How much revenue exposure does Rylaze represent for Jazz?
Rylaze is smaller than Jazz’s leading sleep and epilepsy products but has become a strategically important oncology asset. Based on reported sales of roughly $500 million in 2024 and Jazz consolidated revenue of approximately $3 billion, Rylaze represented a mid-teens percentage of company revenue.
That concentration creates both financial value and portfolio risk. A manufacturing interruption, reimbursement restriction, adverse safety signal, or competing Erwinia product could affect a meaningful portion of Jazz’s revenue growth profile.
How does Rylaze compare with competing asparaginase products?
Rylaze competes primarily with other asparaginase products used in ALL treatment, although many are not direct substitutes for patients with E. coli-derived asparaginase hypersensitivity.
| Product |
Active ingredient |
Sponsor |
Primary role |
Competitive relationship |
| Rylaze |
Recombinant Erwinia asparaginase |
Jazz |
Alternative after hypersensitivity |
Direct competitor to native Erwinia products |
| Erwinaze |
Erwinia chrysanthemi asparaginase |
Jazz historically |
Alternative after hypersensitivity |
Legacy predecessor; supply-constrained or discontinued in the U.S. |
| Oncaspar |
Pegaspargase |
Servier |
First-line asparaginase in many regimens |
Upstream product that can trigger hypersensitivity |
| Asparlas |
Calaspargase pegol-mknl |
Servier |
Long-acting E. coli-derived asparaginase |
Alternative first-line product, not equivalent for allergic patients |
| Native E. coli asparaginase |
E. coli-derived enzyme |
Various |
Standard asparaginase therapy in some markets |
Potential source of hypersensitivity |
| Future biosimilars |
To be determined |
Potential entrants |
Lower-cost biologic alternatives |
Long-term threat after regulatory and patent barriers decline |
Rylaze benefits when patients require continued asparaginase treatment but cannot receive pegaspargase or another E. coli-derived product. It loses share when treatment teams discontinue asparaginase altogether after hypersensitivity or use another Erwinia-derived product.
What generic, biosimilar, and launch risks exist?
A conventional generic launch is not expected because Rylaze is a biologic. The more relevant threat is a biosimilar or a separately developed Erwinia asparaginase.
Near-term risk
Near-term competition is limited by:
- the small patient population;
- complex enzyme manufacturing;
- the need for frequent pharmacokinetic and pharmacodynamic characterization;
- specialized clinical distribution;
- the 2033 reference-product exclusivity period;
- the need to demonstrate comparable activity and immunogenicity.
No publicly disclosed Paragraph IV litigation applies to Rylaze because Paragraph IV is a Hatch-Waxman mechanism for NDAs.
Long-term risk
The larger risk develops after 2033, when a 351(k) biosimilar could seek approval. A competitor could enter before 2033 only if it relies on a separate BLA, a non-reference product strategy, or patent and regulatory positions that do not require biosimilar approval against Rylaze.
Biosimilar uptake may be slower than in large autoimmune or oncology markets because the addressable population is small, treatment decisions are concentrated among pediatric oncology specialists, and supply reliability may carry greater weight than price alone.
What patent litigation or settlement agreements affect Rylaze?
No major publicly disclosed Rylaze patent litigation or Paragraph IV settlement was identified through the company’s 2024 public reporting. The absence of litigation is consistent with the product’s BLA status and the lack of an immediate biosimilar launch window.
A future biosimilar dispute would likely focus on:
- whether Jazz’s process claims cover the entrant’s production method;
- whether formulation or stability claims are infringed;
- whether dosing-method claims are valid and enforceable;
- the scope of any patent listed or exchanged under the BPCIA process;
- the timing of commercial launch relative to the 2033 exclusivity date.
No major third-party licensing transaction for Rylaze has been publicly identified as a principal driver of its commercial economics. Jazz is the principal commercial owner and supplier.
What manufacturing and geographic barriers protect Rylaze?
Rylaze has a specialized manufacturing profile. Production requires recombinant expression, purification, formulation into an injectable product, sterile fill-finish, and cold-chain distribution. Enzyme activity and impurity control are central quality attributes.
Geographically, Jazz’s strongest commercial position is in the United States, where Rylaze received its initial approval and where the product replaced an established Jazz asparaginase franchise. Expansion into Europe and other markets depends on local regulatory approvals, reimbursement, pediatric oncology protocols, and supply-chain execution.
The global opportunity is constrained by disease incidence and treatment infrastructure. High-income markets with established pediatric oncology networks are more accessible than regions where diagnosis, chemotherapy access, and biologic distribution are limited.
What is the outlook for Rylaze revenue and market share?
Rylaze should remain a growth product for Jazz through the late 2020s if it maintains supply reliability and preserves adoption among treatment centers. The most likely trajectory is continued growth at a slower rate than the first two full commercial years, followed by a mature specialty-product phase.
Base-case commercial outlook
- Revenue remains supported by the replacement-asparaginase niche.
- Growth moderates as conversion from Erwinaze reaches maturity.
- Pricing remains high because the product treats a serious, narrow indication with limited substitutes.
- Market expansion depends on broader geographic access and protocol adoption.
- Biosimilar risk remains limited before the early 2030s.
- Revenue concentration increases Jazz’s sensitivity to manufacturing or reimbursement disruption.
Key downside risks
- production interruption or vial shortages;
- substitution by a competing Erwinia-derived enzyme;
- reduced use of asparaginase after hypersensitivity;
- payer restrictions or hospital budget pressure;
- safety findings involving thrombosis, pancreatitis, hepatotoxicity, or hypersensitivity;
- biosimilar entry after the regulatory exclusivity period;
- patent invalidity or non-infringement findings affecting process protection.
Key Takeaways
- Rylaze is Jazz Pharmaceuticals’ recombinant Erwinia asparaginase for ALL and LBL patients hypersensitive to E. coli-derived asparaginase.
- FDA approval occurred on June 30, 2021, under BLA 761179.
- Core biologic exclusivity is expected to run to approximately June 2033, subject to any pediatric extension.
- Orange Book and Paragraph IV mechanisms do not apply because Rylaze is a biologic.
- Jazz Rylaze sales rose from approximately $253 million in 2022 to $376 million in 2023 and about $500 million in 2024.
- The commercial moat rests on biologic exclusivity, specialized manufacturing, limited patient alternatives, and clinical integration into pediatric oncology protocols.
- Long-term competitive risk is centered on 351(k) biosimilars and independently developed Erwinia asparaginase products rather than conventional generics.
- No major publicly disclosed Rylaze patent litigation or settlement was identified through 2024 public filings.
FAQs
Is Rylaze a biosimilar?
No. Rylaze is an FDA-approved biologic product containing recombinant Erwinia asparaginase. It is not a biosimilar to pegaspargase, calaspargase pegol, or native Erwinaze.
Can a generic company file a Paragraph IV challenge against Rylaze?
No. Paragraph IV applies to patents listed for small-molecule products under the Hatch-Waxman Act. A Rylaze competitor would generally use the 351(k) biosimilar pathway or file an independent biologics application.
What drug did Rylaze replace?
Rylaze primarily replaced Erwinaze in the U.S. market for patients who experienced hypersensitivity to E. coli-derived asparaginase. Rylaze was developed to provide a more reliable recombinant supply.
Why is Rylaze expensive despite treating a small population?
The product requires specialized recombinant manufacturing, sterile injectable production, cold-chain handling, frequent dosing, and clinical use in a high-acuity pediatric oncology setting. Limited competition also supports premium pricing.
What is the largest future threat to Rylaze sales?
The largest structural threat is a lower-priced biosimilar or independently developed Erwinia asparaginase product after the regulatory exclusivity period. Near-term threats are more likely to involve supply disruption, reimbursement pressure, or competing clinical protocols.
References
- Jazz Pharmaceuticals plc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
- Jazz Pharmaceuticals plc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
- Jazz Pharmaceuticals plc. (2024-2025). Quarterly earnings releases and investor presentations.
- U.S. Food and Drug Administration. (2021). Rylaze prescribing information and approval letter, BLA 761179.
- U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar biological product development under the Biologics Price Competition and Innovation Act.
